Sugi Predict

Sugi Predict / Compounds / SCHEMBL178417

SCHEMBL178417

SCHEMBL178417

CCCS(=O)(=O)N1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ ALOX15 P16050 1/20 0.47
▸ KDM4E B2RXH2 4/20 0.46
▸ GLA P06280 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ ALDH1A1 P00352 5/20 0.45
▸ LMNA P02545 2/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ CYP1A2 P05177 2/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4277869 0.98 L3MBTL1 (0.47) L3MBTL1ALOX15KDM4EGLAGAA
SCHEMBL31030375 0.95 L3MBTL1 (0.49) L3MBTL1ALOX15KDM4EGLAGAA
SCHEMBL23555007 0.90 L3MBTL1 (0.56) L3MBTL1KDM4EGLAGAAPKM
SCHEMBL13013076 0.86 L3MBTL1 (0.41) L3MBTL1ALOX15GAAPKMALDH1A1
SCHEMBL6901401 0.84 FAAH (0.41) L3MBTL1ALOX15GAAALDH1A1KMT2A
SCHEMBL1069645 0.84 FAAH (0.41) L3MBTL1ALOX15GAAALDH1A1KMT2A
SCHEMBL1321117 0.84 TSHR (0.44) L3MBTL1ALOX15GAAALDH1A1KMT2A
SCHEMBL2738754 0.84 CA1 (0.48) L3MBTL1KDM4EGAAALDH1A1HSD17B10
SCHEMBL6894873 0.82 L3MBTL1 (0.42) L3MBTL1ALOX15GAAKMT2ATSHR
SCHEMBL24767441 0.82 FAAH (0.45) L3MBTL1ALOX15GAAKMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4393923-A1 PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION Yiyou Biotech (Shanghai) Co., Ltd. (CN) 2024-07-03 — — EP disclosed
US-20230286968-A1 ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-09-14 — — US disclosed
WO-2023115327-A1 PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION 中国药科大学 2023-06-29 — — WO disclosed
US-20160022742-A1 MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) 2016-01-28 — — US disclosed
US-9186381-B2 Medicament for liver regeneration and for treatment of liver failure HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) 2015-11-17 — — US disclosed
US-20140141510-A1 MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE MEDIZINISCHE HOCHSCHULE HANNOVER (DE) 2014-05-22 — — US disclosed
EP-1919471-B1 (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR MERCK SHARP & DOHME (NL) 2014-01-08 — — EP disclosed
EP-2323972-B1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2013-07-03 — — EP disclosed
EP-2460805-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION Oncotherapy Science, Inc. (JP) 2012-06-06 — — EP disclosed
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION ONCOTHERAPY SCIENCE, INC. (JP) 2012-03-08 — — US disclosed
US-20090176307-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-07-09 — — US disclosed
US-7491826-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2009-02-17 — — US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 — — US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 — — US disclosed
US-7399866-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2008-07-15 — — US disclosed
US-20060241110-A1 Compounds, compositions, and methods CYTOKINETICS, INCORPORATED 2006-10-26 — — US disclosed
US-20050159416-A1 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2005-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION NR0B1, GRK7, NR5A2 L3MBTL1 4139/4885ALOX15 4378/4885KDM4E 2800/4885
US-20160022742-A1 MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE PYGL, HNF4A, ATF1 L3MBTL1 407/4885ALOX15 2477/4885KDM4E 850/4885
US-20140141510-A1 MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE PYGL, HNF4A, ATF1 L3MBTL1 407/4885ALOX15 2477/4885KDM4E 850/4885
US-20060241110-A1 Compounds, compositions, and methods TNNI3, TNNT2, TNNC1 L3MBTL1 2675/4885ALOX15 4657/4885KDM4E 2542/4885
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same AVPR1B, HRH4, PRLHR L3MBTL1 4431/4885ALOX15 3892/4885KDM4E 1451/4885
US-20050159416-A1 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 L3MBTL1 2750/4885ALOX15 4623/4885KDM4E 2421/4885
US-20230286968-A1 ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, CYP4B1, CYP1B1 L3MBTL1 1818/4885ALOX15 1199/4885KDM4E 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.